Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma executives join board of Innovative Medicines Initiative

This article was originally published in Scrip

Executive Summary

Roch Doliveux, CEO of UCB, has joined the governing board of the Innovative Medicines Initiative (IMI) Joint Undertaking, a public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Also joining the board are Salah-Dine Chibout, global head of investigative toxicology at Novartis, and David Roblin, senior vice-president and head of research at Pfizer's Sandwich laboratories in the UK. IMI aims to foster collaboration in biopharmaceutical R&D between academia, industry, regulatory agencies, patient organisations and small and medium-sized enterprises. It is already sponsoring 15 ongoing research projects and nine further grants will be awarded this summer. Its total budget for 2008-17 is €2 billion. It is chaired by Carlo Incerti, head of R&D Europe at Genzyme.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel